IP Library Granted Patent US 7,423,169
Granted Patent B2
US 7,423,169 · App. 11/511,901 · Granted Sep 9, 2008

Methods for synthesis of acyloxyalkyl derivatives of GABA analogs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,423,169
App. No.
11/511,901
Granted
Sep 9, 2008
Kind
B2
Abstract

The synthesis of 1-(acyloxy)-alkyl carbamates of GABA analogs from 1-haloalkyl carbamates of GABA analogs are described. Also described are new 1-haloalkyl carbamates of GABA analogs.

Claims (57)

1. A compound of Formula (II)

wherein:

X is F, Cl, Br or I;

n is 0 or 1;

R 2 and R 3 are independently hydrogen, alkyl, substituted alkyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl, or optionally, R 2 and R 3 together with the atom to which they are bonded form a cycloalkyl, substituted cycloalkyl, cycloheteroalkyl or substituted cycloheteroalkyl ring;

R 4 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;

R 5 is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, acyl, substituted acyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl, or optionally, R 4 and R 5 together with the atoms to which they are attached form a cycloheteroalkyl or substituted cycloheteroalkyl ring;

R 6 and R 9 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl and substituted heteroarylalkyl;

R 7 and R 8 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroarylalkyl and substituted heteroarylalkyl, or optionally, R 7 and R 8 together with the carbon atom to which they are attached form a cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl or bridged cycloalkyl ring; and

R 10 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryldialkylsilyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl or trialkylsilyl.

2. The compound of claim 1 derived from a GABA analog of Formula (IV):

wherein the GABA analog of Formula (IV) is selected from the group consisting of:

1-Aminomethyl-1-cyclohexane acetic acid (i.e. gabapentin);

1-Aminomethyl-1-(3-methylcyclohexane) acetic acid;

1-Aminomethyl-1-(4-methylcyclohexane) acetic acid;

1-Aminomethyl-1-(4-isopropylcyclohexane) acetic acid;

1-Aminomethyl-1-(4-tert-butylcyclohexane) acetic acid;

1-Aminomethyl-1-(3,3-dimethylcyclohexane) acetic acid;

1-Aminomethyl-1-(3,3,5,5-tetramethylcyclohexane) acetic acid;

1-Aminomethyl-1-cyclopentane acetic acid;

1-Aminomethyl-1-(3-methylcyclopentane) acetic acid;

1-Aminomethyl-1-(3,4-dimethylcyclopentane) acetic acid;

7-Aminomethyl-bicyclo[2.2.1]hept-7-yl acetic acid;

9-Aminomethyl-bicyclo[3.3.1]non-9-yl acetic acid;

4-Aminomethyl-4-(tetrahydropyran-4-yl) acetic acid;

3-Aminomethyl-3-(tetrahydropyran-3-yl) acetic acid;

4-Aminomethyl-4-(tetrahydrothiopyran-4-yl) acetic acid;

3-Aminomethyl-3-(tetrahydrothiopyran-3-yl) acetic acid;

(S)-3-Aminomethyl-5-methyl-hexanoic acid (i.e., pregabalin);

3-Aminomethyl-5-methyl-heptanoic acid;

3-Aminomethyl-5-methyl-octanoic acid;

3-Aminomethyl-5-methyl-nonanoic acid;

3-Aminomethyl-5-methyl-decanoic acid;

3-Aminomethyl-5-cyclopropyl-hexanoic acid;

3-Aminomethyl-5-cyclobutyl-hexanoic acid;

3-Aminomethyl-5-cyclopentyl-hexanoic acid;

3-Aminomethyl-5-cyclohexyl-hexanoic acid;

3-Aminomethyl-5-phenyl-hexanoic acid;

3-Aminomethyl-5-phenyl-pentanoic acid;

3-Aminomethyl-4-cyclobutyl-butyric acid;

3-Aminomethyl-4-cyclopentyl-butyric acid;

3-Aminomethyl-4-cyclohexyl-butyric acid;

3-Aminomethyl-4-phenoxy-butyric acid;

3-Aminomethyl-5-phenoxy-hexanoic acid; and

3-Aminomethyl-5-benzylsulfanyl-pentanoic acid.

3. The compound of claim 1 , wherein the compound of Formula (II) is a compound of Formulae (VII) or (VIII):

and n is 0.

4. The compound of claim 3 , wherein X is chloro, bromo or iodo, R 10 is hydrogen, allyl, benzyl or trimethylsilyl, R 2 is hydrogen, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclohexyl or phenyl and R 3 is hydrogen.

5. The compound of claim 3 , wherein X is chloro, bromo or iodo, R 10 is hydrogen, allyl, benzyl or trimethylsilyl, R 2 is methyl and R 3 is methyl.

6. The compound of claim 5 , wherein X is chloro, bromo or iodo, R 10 is hydrogen, allyl, benzyl or trimethylsilyl, R 2 is methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl or cyclohexyloxycarbonyl and R 3 is methyl.

7. The compound of claim 3 , wherein X is chloro, bromo or iodo, R 1 is hydrogen, allyl, benzyl or trimethylsilyl, and R 2 and R 3 together with the atom to which they are attached form a cyclohexyl ring.

8. The compound of claim 3 , wherein X is chloro, R 10 is hydrogen, allyl, benzyl or trimethylsilyl, R 2 is hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl and R 3 is hydrogen.

9. The compound of claim 3 , wherein X is chloro, R 10 is hydrogen, allyl, benzyl or trimethylsilyl, R 2 is methyl, n-propyl or isopropyl, and R 3 is hydrogen.

10. The compound of claim 3 , wherein X is chloro, R 10 is hydrogen, R 2 is methyl, and R 3 is hydrogen.

11. The compound of claim 3 , wherein X is chloro, R 10 is allyl, R 2 is methyl, and R 3 is hydrogen.

12. The compound of claim 3 , wherein X is chloro, R 10 is benzyl, R 2 is methyl, and R 3 is hydrogen.

13. The compound of claim 3 , wherein X is chloro, R 10 is trimethylsilyl, R 2 is methyl, and R 3 is hydrogen.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 20, 2021
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ARBOR PHARMACEUTICALS, LLC; WILSHIRE PHARMACEUTICALS, INC.; XENOPORT, INC.
Reel/Frame 057880/0174 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2018
From: XENOPORT, INC.
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 046633/0753 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2018
From: ARBOR PHARMACEUTICALS, LLC
To: XENOPORT, INC.
Reel/Frame 046449/0306 →
SECURITY INTEREST Recorded Jul 6, 2016
From: ARBOR PHARMACEUTICALS, LLC; XENOPORT, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 039266/0345 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2008
From: RAILLARD, STEPHEN P.; ZHOU, CINDY X.; YAO, FENMEI; MANTHATI, SURESH KUMAR; XIANG, JIA-NING; GALLOP, MARK A.
To: XENOPORT, INC.
Reel/Frame 021623/0194 →